Quince Therapeutics, INC Form 4 insider transactions

Director Christopher J. Senner of Quince Therapeutics acquired 35,274 stock options in lieu of his 2025 annual director cash retainer.

Quince Therapeutics CEO Dirk Thye recently purchased a significant number of company shares, signaling confidence in the firm's prospects.

Charles S. Ryan, President of Quince Therapeutics, recently purchased 48,387 shares of QNCX common stock at an average price of $0.65.

Brendan Hannah, Chief Business Officer and COO of Quince Therapeutics, recently acquired additional shares of the company's common stock through a series of open market purchases.

Director David Lamond acquired 27,000 employee stock options in Quince Therapeutics, Inc. on June 5, 2024.

Margaret McLoughlin, a director of Quince Therapeutics, reported the acquisition of stock options for 27,000 shares on June 5, 2024.

Director Una S. Ryan acquired 27,000 shares of Quince Therapeutics through a stock option grant on June 5, 2024.

Christopher J. Senner, a director of Quince Therapeutics, Inc., acquired 27,000 employee stock options on June 5, 2024.

Director June Bray acquired 27,000 employee stock options in Quince Therapeutics, Inc. on June 5, 2024.

Luca Benatti, a director of Quince Therapeutics, Inc., acquired stock options for 27,000 shares on June 5, 2024.

Director Rajiv Patni acquired stock options for 13,500 shares of Quince Therapeutics, Inc. at an exercise price of $0.82 on June 5, 2024.

Brendan Hannah, Chief Business Officer and COO of Quince Therapeutics, exercised stock options and disposed of shares on June 4, 2024.